Related Experiment Video
Updated: Jun 21, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Outcome of mildly symptomatic or asymptomatic obstructive hypertrophic cardiomyopathy: a long-term follow-up study
Paul Sorajja1, Rick A Nishimura, Bernard J Gersh
1Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA. paul.sorajja@mayo.edu
Insights
Minimally symptomatic obstructive hypertrophic cardiomyopathy (HCM) patients have slight excess mortality. However, high left ventricular outflow tract (LVOT) gradients indicate a high risk for heart failure and death in obstructive HCM.
Area of Science:
- Cardiology
- Internal Medicine
Background:
- Obstructive hypertrophic cardiomyopathy (HCM) may affect most patients, regardless of symptoms.
- Prognosis for minimally symptomatic obstructive HCM is not well-defined.
Purpose of the Study:
- To characterize the prognosis of patients with obstructive hypertrophic cardiomyopathy (HCM) who have minimal symptoms.
Main Methods:
- 544 adult obstructive HCM patients (mean age 59 years) without severe symptoms underwent Doppler echocardiography and clinical follow-up (median 9.3 years).
Main Results:
- Overall cohort had slight excess mortality compared to the general US population (10-year survival 69.3% vs. 71.9%).
- High resting left ventricular outflow tract (LVOT) gradients (>4 m/s) were linked to significantly impaired survival (53% at 10 years) and increased risk of death or severe symptoms (68% within 10 years).
- Age, prior stroke, and LVOT gradient severity predicted mortality.
Conclusions:
- Obstructive HCM patients with mild/no symptoms have minimal excess mortality.
- Markedly elevated resting LVOT gradients identify patients at high risk for heart failure and death.
- Findings may influence therapeutic strategies, including the timing of septal reduction therapy.
Objectives:
The purpose of this study was to characterize the prognosis of minimally symptomatic patients with obstructive hypertrophic cardiomyopathy (HCM).
Background:
Recent data have suggested that obstruction may be present in the majority of HCM patients, irrespective of cardiac symptoms. The prognosis of minimally symptomatic obstructive HCM remains poorly defined.
Methods:
We examined 544 consecutive adult patients (age 59 +/- 16 years; 55% men) with obstructive HCM documented by Doppler echocardiography who were free of severe cardiac symptoms, and we performed clinical follow-up (median 9.3 years).
Results:
There was only a slight excess mortality of the cohort in comparison to the expected survival of a similar U.S. general population (10-year observed vs. expected survival, 69.3% vs. 71.9%; p = 0.04) and 46% of the deaths were attributable to noncardiac causes. However, there was a clear relation between increasing severity of the left ventricular outflow tract (LVOT) gradient and outcome. For patients with high resting gradients (Doppler peak velocity >4 m/s), survival was significantly impaired (53% at 10 years; p = 0.001 vs. expected), and death or severe symptoms occurred in 68% of these patients within 10 years after the initial evaluation. Conversely, there was no impairment of long-term survival for patients with less-severe resting obstruction. Independent predictors of mortality in the entire cohort were age, prior stroke, and LVOT gradient severity.
Conclusions:
Patients with obstructive HCM and mild or no symptoms have only slight excess mortality. However, patients with markedly elevated resting LVOT gradients are at a high risk of heart failure and death. These findings may have important implications for therapy, including the timing of septal reduction therapy.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy VII: Pre and Post Operative Nursing Management
Cardiomyopathy II: Dilated Cardiomyopathy
Heart Failure II: Pathophysiology
Hypertension III: Clinical Manifestations and Diagnostic Studies
